<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 h post treatment. B: Western blot analysis of the levels of uncleaved PARP, cleaved PARP and cleaved (active) caspase 3 72 h post carboplatin treatment (0–200 µM) in PC9 and A549 cells. Actin was used as a loading control. C, D: Flow cytometric analysis of PC9 (C) and A549 cells (D) treated with carboplatin (100 µM) or vehicle. Apoptotic cells were identified by Annexin V-Alexafluor488 (λ Ex/Em = 495/519 nm) and necrotic cells by 7-AAD (λ Ex/Em = 546/647 nm). Population Q4 represents viable cells, whereas population Q3 represents apoptotic cells that have low 7-AAD fluorescence and stain with Annexin V. Population Q2 represents secondary apop...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>A-F: A1847, A2780, and OVCAR10 were treated with 20 µg/mL epimorphin for 3 days. After 3 days, ep...
<p>OVCA429/pCEG (<i>A</i>, <i>C</i>) and OVCA429/NICD3 (<i>B</i>, <i>D</i>) cells were treated with ...
<p>A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blo...
<p>(A) Box plots showing statistical distribution of the individual apoptosis rates, expressed as do...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
This study demonstrated that cisplatin and carboplatin stimulate apoptosis in human retinoblastoma Y...
<p>A, B, Analysis of pH2AX and pChk2 expression and PARP cleavage in HCT116, HCT116+3, and HCT116+3+...
Purpose: In order to understand the apoptosis pathway in tumor cells, differences in cell morphology...
<p>DNA-mismatch repair in arrested cells recovering to the proliferating population is assumed to be...
<p>ABT-888 (20 μM or 200 μM) was used to treat MCF7 and individually HP1-depleted MCF7 cells for 72 ...
<p>Cells were treated with or without 2.5 μM MPT0B169 for 24 and 48 h, and the following experiments...
<p>KTC-1 cells were left untreated as controls (<b>A</b>), or treated with 20 MBq/ml <sup>131</sup>I...
<p>(<b>A</b>) – Samples from PC3 and LNCaP cells treated without/with (S)-2 (2.5 and 5 µM) for 24 h ...
<p>A: Chemical structure of <sup>18</sup>F-ICMT-11. B: Dose-dependent changes in caspase 3/7 activit...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>A-F: A1847, A2780, and OVCAR10 were treated with 20 µg/mL epimorphin for 3 days. After 3 days, ep...
<p>OVCA429/pCEG (<i>A</i>, <i>C</i>) and OVCA429/NICD3 (<i>B</i>, <i>D</i>) cells were treated with ...
<p>A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blo...
<p>(A) Box plots showing statistical distribution of the individual apoptosis rates, expressed as do...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
This study demonstrated that cisplatin and carboplatin stimulate apoptosis in human retinoblastoma Y...
<p>A, B, Analysis of pH2AX and pChk2 expression and PARP cleavage in HCT116, HCT116+3, and HCT116+3+...
Purpose: In order to understand the apoptosis pathway in tumor cells, differences in cell morphology...
<p>DNA-mismatch repair in arrested cells recovering to the proliferating population is assumed to be...
<p>ABT-888 (20 μM or 200 μM) was used to treat MCF7 and individually HP1-depleted MCF7 cells for 72 ...
<p>Cells were treated with or without 2.5 μM MPT0B169 for 24 and 48 h, and the following experiments...
<p>KTC-1 cells were left untreated as controls (<b>A</b>), or treated with 20 MBq/ml <sup>131</sup>I...
<p>(<b>A</b>) – Samples from PC3 and LNCaP cells treated without/with (S)-2 (2.5 and 5 µM) for 24 h ...
<p>A: Chemical structure of <sup>18</sup>F-ICMT-11. B: Dose-dependent changes in caspase 3/7 activit...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>A-F: A1847, A2780, and OVCAR10 were treated with 20 µg/mL epimorphin for 3 days. After 3 days, ep...
<p>OVCA429/pCEG (<i>A</i>, <i>C</i>) and OVCA429/NICD3 (<i>B</i>, <i>D</i>) cells were treated with ...